Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax (2022 - 2026)

Centessa Pharmaceuticals (CNTA) has 5 years of Long-Term Deferred Tax data on file, last reported at $24.2 million in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $24.2 million, down 8.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.2 million (down 8.41% YoY), and the FY2025 annual result was $24.8 million, down 6.8% from the prior year.
• Long-Term Deferred Tax retreated to $24.2 million in Q1 2026 per CNTA's latest filing, from $24.8 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $29.6 million in Q4 2023 and troughed at $3.5 million in Q4 2022.
• A 5-year average of $25.1 million and a median of $26.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2023 and 2025: Long-Term Deferred Tax jumped 744.16% in 2023, then declined 11.27% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $3.5 million in 2022, then jumped by 744.16% to $29.6 million in 2023, then dropped by 10.32% to $26.6 million in 2024, then retreated by 6.8% to $24.8 million in 2025, then fell by 2.45% to $24.2 million in 2026.
• Business Quant data shows CNTA's Long-Term Deferred Tax at $24.2 million in Q1 2026, $24.8 million in Q4 2025, and $25.0 million in Q3 2025.